0
Your cart

Your cart is empty

Books > Business & Economics > Industry & industrial studies > Manufacturing industries > Pharmaceutical industries

Buy Now

Bad Medicine - The Prescription Drug Industry in the Third World (Hardcover) Loot Price: R1,803
Discovery Miles 18 030
Bad Medicine - The Prescription Drug Industry in the Third World (Hardcover): Milton Silverman, Mia Lydecker, Philip R Lee

Bad Medicine - The Prescription Drug Industry in the Third World (Hardcover)

Milton Silverman, Mia Lydecker, Philip R Lee

 (sign in to rate)
Loot Price R1,803 Discovery Miles 18 030 | Repayment Terms: R169 pm x 12*

Bookmark and Share

Expected to ship within 12 - 17 working days

Donate to Gift Of The Givers

Silverman, Lydecker, and Lee - who took upon themselves the seemingly Sisyphean task of exposing the abuses of the pharmaceutical industry (Prescriptions for Death: The Drugging of the Third World, 1982, etc.) - now reexamine the situation in the Third World and conclude that a worldwide crisis exists. The present survey, begun in 1987, indicates that most multinational drug companies, under pressure from within and without, have improved the way they label and market their products. But apparently the public hasn't benefited - for, the authors contend, scores of useless and dangerous drugs are now put out by local or domestic firms, small in size but large in political clout. Fraudulent drugs abound, and badly needed ones are unavailable. The authors cite some small success stories - India's ban on deadly, high-dosage hormones, and a pilot project in Gambia in which drug companies and the government cooperated to set up a drug-distribution system - but they observe that, in most developing nations, drug-regulation agencies are corrupt, weak, and underfunded, and their workers poorly trained. Bribery, the authors note, is a way of life throughout the Third World. They conclude that what's needed is constant surveillance, as well as continuous consultation among consumer advocates, the drug industry, government agencies, and the medical and pharmacy professions, with the World Health Organization leading the way. The scrutiny is close, the research impressive, though the presentation is so detailed that it may overwhelm all but the most concerned reader. Still, a thorough assessment of a perilous situation. (Kirkus Reviews)
The pharmaceutical industry has long and vehemently insisted that it has the willingness, the dedication, and the ability to police itself to insure that the public will not be unnecessarily harmed or defrauded. As the record shows with painful clarity, however, virtually no industry or professional group has ever adequately policed itself, and the pharmaceutical industry is no exception. Where the most flagrant abuses have been exposed and corrected, major credit must probably be divided among the media that publicized the situation, consumer groups that applied pressure, government officials who took actions that were often unpopular, and individual members of the pharmaceutical industry who had the courage to face up to their social responsibilities.
In this book, the authors turn their attention to what happened in Third World countries when, because of worldwide pressures, the multinational drug companies largely corrected their notorious abuses. On the basis of painstaking research, much of it conducted in a great many Third World countries, the authors conclude that a plethora of small local firms have filled the dishonest sales channels vacated by the multinationals. The authors show in great detail how local drug firms in the Third World have taken advantage of loose regulatory practices and unscrupulous behavior on the part of regional and national health care professionals to promote the sale of dangerous or worthless drugs as remedies for diseases for which they were never intended. Warnings of bad side effects are omitted from promotional literature, drugs are sold that have not had proper trials, and drug firms have often bribed government officials, doctors, and hospital administrators in order to gain favorable treatment in the importation and sale of their products. Among the many topics treated in this book are the controversy over inexpensive generic drugs (including disclosures of fraud and bribery in the U.S. Food and Drug Administration), the actions of consumer groups, and the key role of government in preventing abuses by drug firms. The authors describe a remarkable attempt in Bangladesh, one of the poorest of all the developing countries, to develop a high-quality local drug industry. They also present as case histories reports on three extremely important drug products or groups--the dipyrones (for control of pain and fever), high-dosage estrogen-progesterone hormone products (for use in pregnancy tests), and clioquinol or Enterovioform (for treatment of diarrhea)--all of which were or still are centers of worldwide, heated controversy.

General

Imprint: Stanford University Press
Country of origin: United States
Release date: May 1992
First published: 1992
Authors: Milton Silverman • Mia Lydecker • Philip R Lee
Dimensions: 229 x 152 x 30mm (L x W x T)
Format: Hardcover - Cloth / Cloth
Pages: 380
ISBN-13: 978-0-8047-1669-7
Categories: Books > Business & Economics > Industry & industrial studies > Manufacturing industries > Pharmaceutical industries
LSN: 0-8047-1669-2
Barcode: 9780804716697

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners